Pharma has a new way to tell the same story: “It’s not a new drug—it’s a new value proposition.”
That’s the subtext behind the latest wave of premium pricing for repurposed medicines—older compounds reintroduced with fresh indications, updated formulat…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is a decoy. Patent filings are the real map.
If you’ve been watching Russia’s pharmaceutical strategy, you’ve probably heard the phrase “third wheel” rule—an idea that sounds technical, bureaucratic, and ultimately secondary…

Europe’s “Divisional Patent” loophole is quietly reshaping the generics race—and Big Pharma knows exactly how to use it.
If you’ve ever wondered why some generic medicines seem to get stuck in legal limbo long after the science is settled, the answer m…

Pharma patent litigation used to be a $50M problem.
Now, for some companies, it’s closer to $5M.
That’s not a fantasy number—it’s the outcome of a shift in how drugmakers (and their counsel) approach patent disputes: earlier, tighter, and more strategi…

PBMs don’t just “manage formularies.” They shape the economics of every drug launch, every contract renegotiation, and—quietly—every patient’s access decision.
If you’re a pharma executive, the last few years have made one thing painfully clear: rebate…

Mark Cuban’s “cost-plus” pricing isn’t just a pricing story—it’s a patent story.
For years, the pharma industry has sold a familiar narrative: patents are the engine that funds innovation, and high launch prices are the fuel that keeps the pipeline mov…

Should you file a provisional patent for your drug invention? The honest answer.
Most founders in biotech don’t lose because their science is weak. They lose because their strategy is fuzzy—especially at the earliest stage, when time is scarce and the …

The “patent cliff” isn’t a cliff. It’s a countdown.
If you’re waiting until a drug’s exclusivity window is ending to think about supply, you’re already late.
In pharma, the transition from branded monopoly to generic competition is often framed as a …

The 180-Day FDA Exclusivity Race Isn’t a Sprint—It’s a Strategy War
In generic and biosimilar development, everyone talks about the finish line: the coveted 180-day FDA exclusivity window. But the real story isn’t about who moves fastest. It’s about wh…